### Comment:
Did you listen to the presentation today?  Overall seemed very positive - the market doesn’t seem to agree.

### REPLY:
I thought it was pretty good, about what I expected. I particularly am excited that they might be able to use a literature/historical control arm as that will drastically reduce the cost of the ph3 trials.  
  
 I bought some more $25 LEAPs for $3.50 to average down. I’m guessing theirs not going to be any near term price catalysts unfortunately.    
  
 I still do believe that with multiple shots on goal with OMS721 they’re positioned very well.

### END.